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824 LETTERS TO THE EDITORIn our cohort of patients with severe asthma, the majority
receiving very high doses of inhaled or systemic corticosteroids, a
blood eosinophil count of greater than 0.45 3 109 cells/L can
correctly predict sputum eosinophilia in 9 of 10 cases. We have
included only patients with severe asthma in our study, and there-
fore we believe our results are important because these are the pa-
tients who will be considered for novel TH2-targeting biologic
agents.
The search for biomarkers of airway inflammation has been
made more urgent by the advance of novel therapies that act
specifically by targeting this inflammation. To this end, recent
studies that aimed to investigate the potential benefit of mepoli-
zumab in patients with eosinophilic asthma identified patients by
using blood eosinophil cutoffs as low as 0.153 109 cells/L.7,8 As
demonstrated both here and in the article from the Severe Asthma
Research Program group,4 this cutoff would include many pa-
tients who in fact do not have contemporaneous sputum eosino-
philia (more than half in this study) and therefore potentially
would not be in the group of patients who could benefit from treat-
ment. The consequence of this in a trial of a biologic agent is that
the magnitude of benefit could be underestimated or even missed,
as happened previously when mepolizumab was trialed in unse-
lected patients.9 The other potential consequence of using blood
eosinophil counts as a surrogate for sputum is the very high risk
of false-negative results; from our data, approximately 1 in 5
patients without blood eosinophilia had airway eosinophilia and
hence could be missed by using this selection method. Choosing
a simple and universally available biomarker (blood eosinophil
counts) is attractive, but in this case does not lead to a personal-
ized medicine approach.
In conclusion, we have shown that using a cutoff of 0.45 3
109 cells/L for blood eosinophilia can usefully predict airway
eosinophilia in patients with severe asthma receiving high
levels of treatment. However, we agree with Hastie et al3
that lower cutoffs are not useful. We would propose that study
design for novel antieosinophil therapies could use this higher
cutoff to investigate the effect of these therapies but that pa-
tients should also be included with airway but not blood eosin-
ophilia, as previously described.8 In the meantime, more work
needs to be done to develop useful minimally invasive and ac-
curate surrogate markers for airway inflammation, including
composite biomarkers comprising, for example, exhaled nitric
oxide and serum periostin levels together with blood eosino-
phil counts.
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Vitamin D enhances production of soluble
ST2, inhibiting the action of IL-33
To the Editor:
Vitamin D insufficiency is an environmental factor that has
been strongly associated with asthma and its severity.1 The genes
IL33 and IL1RL1 have been repeatedly identified as predisposing
to asthma risk in genome-wide association studies.2 IL-33 is an
alarmin cytokine that acts on multiple pulmonary cell types,
including TH2 lymphocytes, mast cells, and innate lymphoid
cells, to promote TH2-type cytokine secretion and airway inflam-
matory responses of the kind observed in asthmatic patients.3,4
The receptor for IL-33 is encoded by IL1RL1; differential splicing
of the gene can produce a functional membrane-bound receptor
(ST2L) or a soluble decoy receptor (sST2).5 Therefore we inves-
tigated whether IL1RL1 is regulated by vitamin D in cells relevant
to asthma. We did this first by measuring gene expression by
means of quantitative real-time PCR with 2 different TaqMan
probe sets: Hs01073300, which detects mRNA splice variants en-
coding both the membrane-bound and soluble receptors (the total
mRNA for IL1RL1), and Hs00249389, which detects mRNA only
for the splice variant encoding the membrane-bound receptor
ST2L (Fig 1, A). Methods are provided in this article’s Online Re-
pository at www.jacionline.org.
Both probe sets display similar efficiency of amplification (data
not shown). Human primary bronchial epithelial cells (HBECs),
CD4 lymphocytes, CD8 lymphocytes, eosinophils, and LUVA
mast cells were cultured in the presence or absence of 1a,25-
dihydroxyvitamin D3 (1,25[OH]D3), the active form of vitamin
D (Fig 1, B-D, and see Fig E1, A and B, in this article’s Online Re-
pository at www.jacionline.org). Addition of 1,25(OH)D3 signif-
icantly increased the total number of IL1RL1 mRNA transcripts
expressed by HBECs and CD4 and CD8 lymphocytes, as
measured by using the Hs01073300 probe set. However,
1,25(OH)D3 did not significantly increase expression of
IL1RL1 mRNA transcripts by primary eosinophils and LUVA
mast cells, despite it significantly increasing expression of the
FIG 1. Vitamin D induces expression of sST2. A, Schematic for IL1RL1mRNA: the 2 splice variants are differ-
entially detected in PCR by using the probe sets Hs01073300 and Hs00249389. B-D, IL1RL1 transcripts de-
tected by each probe set in cultures of HBECs at 24 hours (Fig 1, B; n 5 7) and CD4 (Fig 1, C) and CD8
(Fig 1, D) lymphocytes at 7 days (n 5 6). E-H, sST2 protein in culture supernatants of HBECs at 24 hours
(Fig 1, E; n 5 6), CD4 lymphocytes at 7 days (Fig 1, F; n 5 6), and HBECs (Fig 1, G; n 5 6) and HNECs at
24 hours (Fig 1, H; n 5 5). ns, Not significant. *P <_ .05, **P <_ .01, and ***P <_ .001.
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to be induced by vitamin D (see Fig E1, A and B).
Higher IL1RL1 expression levels were detected with the
Hs01073300 probe set than with the Hs00249389 probe set in
HBEC and lymphocyte cultures. Although 1,25(OH)D3 increased
the total copies of IL1RL1 mRNA measured by using the
Hs01073300 probe set in these cell types, it did not increase
the number of transcripts encoding ST2L detected with
Hs00249389, indicating that vitamin D selectively upregulates
the expression of mRNA for the soluble decoy receptor sST2.
sST2 concentrations in culture supernatants were measured by
means of ELISA to confirm the findings of gene expression studies
at the protein level. sST2 concentrations were significantly
increased by 1,25(OH)D3 in both HBEC and CD4 lymphocyte
cultures (Fig 1, E and F). In contrast, CD8 lymphocytes produced
less than 200 pg/mL sST2 in all conditions, and there was no ev-
idence of upregulation by 1,25(OH)D3 (data not shown).
Vitamin D circulates primarily as the inactive precursor 25-
hydroxyvitamin D3 (25[OH]D3); however, epithelial cells consti-
tutively express CYP27B1, the enzyme that converts 25(OH)D3 to
1,25(OH)D3.6 HBECs cultured with 100 nmol/L 25(OH)D3, a
physiologic concentration, increased expression of IL1RL1 (see
Fig E1, C) and produced significantly greater amounts of sST2
(Fig 1, G). Primary human nasal epithelial cells (HNECs) culturedwith a similar concentration range of 25(OH)D3also showed a clear
concentration-dependent increase in sST2 production (Fig 1, H).
CD4 lymphocytes did not respond to 25(OH)D3, which is consis-
tent with their lower expression of CYP27B1 (see Fig E1, D).
An IL-33 sensitive bioassay was developed using the LUVA
mast cell line to test the biological activity of sST2. Twenty-four
hours of exposure of LUVA cell cultures to IL-33 resulted in
marked homotypic aggregation, which was associated with
increased expression of CD54 (intercellular adhesion molecule
1; see Fig E2, A and B, in this article’s Online Repository at www.
jacionline.org). IL-33 increased CD54 expression on LUVA cells
in a concentration-dependent manner (Fig 2, A). Other stimuli
can also induce mast cell CD54 expression, and a similar
concentration-dependent induction of CD54 expression was
achieved with a combination of IFN-g and IL-4 (Fig 2, A). Treat-
ment of LUVA cells with a recombinant sST2-Fc chimera signif-
icantly inhibited IL-33–induced CD54 expression (P 5 .0076;
Fig 2, B, and see Fig E2, C) but not IFN-g plus IL-4–induced
CD54 expression (see Fig E2, D). Addition of 1,25(OH)D3 itself
to LUVA cell cultures did not significantly alter constitutive or
induced CD54 expression (P > .05; see Fig E2, E), as previously
reported for another mast cell line.7
To examine the effect of vitamin D–enhanced epithelial sST2
production on the IL-33 bioassay, HNECs were cultured in the
FIG 2. Conditioned medium from vitamin D–treated epithelial cultures inhibits IL-33–induced expression of
CD54 by LUVA cells.A, Induction of CD54 on LUVA cells above that of unstimulated cells by different stimuli
in the presence of conditionedmedium from control epithelial cell cultures (n5 7). B, Effect of IL-33 on CD54
expression is inhibited by recombinant sST2 (n5 6). C and D, CD54 expression on LUVA cells cultured with
conditioned medium with or without cell stimulation. E, Percentage reduction in stimuli-induced CD54
expression on LUVA cells cultured with conditioned medium from 25(OH)D3-treated epithelial cell cultures
compared with control epithelial cell cultures (n 5 7).MFI, Mean fluorescence intensity; ns, not significant.
*P <_ .05, **P <_ .01, ***P <_ .001, and ****P <_ .0001.
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supernatants were added to cultures of LUVA cells stimulated
with concentrations of IL-33 or IFN-g plus IL-4 that induced
comparable CD54 expression. Conditionedmedium from vitamin
D–treated epithelial cells significantly reduced IL-33–induced
CD54 expression on LUVA cells compared with conditioned
medium from matched epithelial cell cultures not treated with
vitamin D (P 5 .015; Fig 2, C and E). In contrast, there was no
significant difference in IFN-g plus IL-4–induced CD54 expres-
sion between LUVA cells cultured with the different epithelial
cell–conditioned media (P > .05; Fig 2, D and E). Although me-
diators in the epithelial cell–conditioned medium other than sST2
might conceivably have affected LUVA cell CD54 expression, the
selective effect of vitamin D treatment on IL-33–induced CD54
expression suggests that the sST2 in the vitamin D–treated epithe-
lial cell supernatants is biologically active.
The capacity of IL-33 to induce production of TH2-type proin-
flammatory cytokines by multiple cell types likely underpins the
reported genetic associations of IL33 and IL1RL1 with asthma.
Here we report the novel finding that 100 nmol/L vitamin D isable to augment expression by epithelial cells and lymphocytes
of the soluble decoy receptor sST2, which in turn inhibits the ac-
tions of IL-33. Importantly, this effect occurs at physiologic con-
centrations (vitamin D sufficiency is defined as a serum 25[OH]D
level of 75 to 150 nmol/L), and similar concentrations of
1,25(OH)D3 have been shown to be able to be generated from
25(OH)D3 in culture.1 We hypothesize that the capacity of
vitamin D to augment the synthesis of an inhibitor of IL-33 in
situ in the airways mucosa is of potential benefit in the limitation
of asthmatic mucosal inflammation. Furthermore, this might in
part account for the paradox that epidemiologic studies have
repeatedly revealed associations between vitamin D insufficiency
and both the risk of more severe asthma1 and increased serum IgE
concentrations,8 whereas other studies have reported that in cul-
ture vitamin D can act directly on TH2 lymphocytes to promote
TH2 cytokine secretion (eg, Boonstra et al
9). The apparent bene-
ficial association of vitamin D in asthma in vivo, which in many
patients is a TH2-type cytokine pathology, suggests that the direct
action of vitamin D in promoting TH2 lymphocyte responses is
less important in vivo than other vitamin D–mediated
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the induction of regulatory mechanisms) in inhibiting TH2-type
cytokine responses. Because the enhancement by vitamin D of
sST2 production is concentration dependent, this supports thera-
peutic strategies to boost pulmonary vitamin D levels to reduce
asthmatic inflammation.
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Claudin-1 polymorphism modifies the effect of
mold exposure on the development of atopic
dermatitis and production of IgE
To the Editor:
Skin barrier dysfunction, which plays a key role in the initiation
of atopic dermatitis (AD), may be associated with both genetic
susceptibility and environmental risk factors for AD. Importantly,
the skin of patients with AD may exhibit not only loss-of-function
mutation in filaggrin1 but also defects in tight junction (TJ) func-
tion,2 all of which can contribute to decreased skin barrier function.
Consistent with these observations, disruption of the epidermal
barrier (comprising the stratum corneum and epithelial TJs) is
now recognized as a common feature in subjects with AD.
A recent study showed that the nonlesional epithelium of patients
with AD exhibited marked defects in TJs, possibly due to reduced
levels of claudin-1 (CLDN1), a key adhesive protein.2
Elevated levels of fungal and bacterial components in house
dust,3 or diversity of the mold components in the environment,4
may have protective effects to the development of allergic
diseases. However, exposure to indoor mold is a risk factor for
childhood asthma and allergy,5 and exposure to fungi in early
infancy is associated with an increased risk of AD.6 The reason
for these discrepancies among the effects of various molds on
allergy-related health outcomes remains largely unknown.
Several studies have focused on gene-environment interactions
in the context of mold exposure. Our group’s previous studies
showed that mold exposure is a risk factor for the development of
AD and allergic rhinitis in children with susceptibility.6,7
However, no study has yet examined the associations between
CLDN1 polymorphisms and mold exposure, or investigated
whether such an association has a functional impact on the
development of AD. In this study, we examined the combined
effect of the rs9290929 polymorphism, located in the CLDN1
promoter, and mold exposure during the first year of life on the
development of AD symptoms and production of IgE and also
investigated the response of cell and mouse skin tissue mediated
by mycotoxin (patulin). The definition of AD, the characteristics
of the study subjects, the total IgE levels, and the genotyping of
the CLDN1 polymorphism are described in the Methods section
in this article’s Online Repository at www.jacionline.org. Our
results demonstrated that visible mold exposure during the first
year of life was an independent risk factor for lifetime AD
symptoms (adjusted odds ratio [aOR], 1.60; 95% CI, 1.26-2.03)
in the general population-based study (see Table E2 in this
article’s Online Repository at www.jacionline.org). CLDN1
polymorphism was associated with susceptibility to AD in
the hospital-based case-control study (aOR, 1.48; 95% CI,
1.04-2.12) (see Table E3 in this article’s Online Repository at
www.jacionline.org). We then analyzed the association between
CLDN1 polymorphism and mold exposure in the general
METHODS
Cell-culture reagents
Ultrahigh-purity 1,25(OH)D3 and 25(OH)D3 (Enzo Life Sciences, Exeter,
United Kingdom) were placed in aliquots dissolved in dimethyl sulfoxide
(Sigma-Aldrich, Gillingham, United Kingdom). Recombinant proteins were
obtained as follows: IL-33, IFN-g, IL-4, human sST2-Fc chimera, and isotype
were all from R&D System (Abingdon, United Kingdom).
Primary human epithelial cell culture
Primary HBECs were acquired from Lonza (Basel, Switzerland) and
locally from endobronchial brushings obtained at fiberoptic bronchoscopy
from adult volunteers (Guy’s Research Ethics Committee, South London REC
Office 3, REC approval no. 09/H0804/108, March 16, 2010). HNECs were
obtained from resected nasal turbinates from adult patients undergoing nasal
turbinectomy for clinical indications (City Road & Hampstead NRES
Committee London, REC approval no. 12/LO/1931, January 14, 2013).
Excised tissue was dissected and then treated with Liberase TL (Roche
Diagnostics, Indianapolis, Ind) before isolation of epithelial cells with CD326
magnetic microbeads (magnetic cell sorting [MACS]; Miltenyi Biotech,
Bisley, United Kingdom). Cells were expanded in flasks of Bronchial
Epithelial Cell Growth Medium, which was constituted by supplementing
Bronchial Epithelial Basal Medium (Lonza) with SingleQuot Supplements
(Lonza). Epithelial cells were used for experiments at passages 3 to 5.
Cell purity after passage checked by means of flow cytometry with an
allophycocyanin-labeled anti-human CD326 antibody (Miltenyi Biotech) and
appropriate isotype control was greater than 99%.
Monolayers for cell-culture experiments were inspected daily by using
light microscopy, and once approaching confluence, medium was changed to
Bronchial Epithelial Cell Growth Medium containing all SingleQuot Supple-
ments except bovine pituitary extract, retinoic acid, and hydrocortisone.
Cell-culture experiments with HBECs were conducted with triplicate wells
for each condition in each experiment. For conditioned medium, culture
supernatant was collected and centrifuged at 250g for 7 minutes before ali-
quots of the supernatant were used as conditioned medium.
Peripheral blood lymphocyte culture
PBMCs were obtained by means of density centrifugation with Lympho-
prep density gradient medium (Axis-Shield, Dundee, United Kingdom).
CD41 and CD81 lymphocytes were isolated by using Dynabeads (Invitrogen,
Life Technologies, Paisley, United Kingdom). Cell purity was assessed by
means of flow cytometry with appropriate isotype controls and was 95% to
98% for all experiments. Lymphocytes were cultured at 1 3 106 cells/mL in
RPMI 1640 (Gibco, Life Technologies, Paisley, United Kingdom) supple-
mented with 50 U/mL IL-2 (Eurocetus, Harefield, United Kingdom), 10%
FBS (PAA, Yeovil, United Kingdom), 2 mmol/L L-glutamine (Gibco, Life
Technologies), and 0.1% 50 mg/mL gentamicin (Gibco, Life Technologies)
on cell-culture plates coated with anti-CD3 (1 mg/mL; OKT-3) for 7 days.
Peripheral blood eosinophil culture
PBMCs were obtained, as described previously. Eosinophils were isolated
with a MACS negative selection kit (MACS, Miltenyi Biotech), according to
an adapted manufacturer’s protocol. Cell purity was 96% to 99% for all
experiments. Eosinophils were cultured at 1 3 106 cells/mL in RPMI 1640
supplemented with 10% FBS, 2 mmol/L L-glutamine, and 0.1% 50 mg/mL
gentamicin for 20 hours.
Quantitative real-time PCR
Epithelial cell monolayers were lysed with Qiazol reagent (Qiagen,
Manchester, United Kingdom) before storage at 2808C pending extraction
of mRNA with an miRNeasy Mini Kit (Qiagen), according to an adapted
manufacturer’s protocol with an off-column DNA digest with TurboDNase
(Ambion, Life Technologies, Paisley, United Kingdom). mRNAwas extracted
from lymphocyte culture cell pellets by using an RNeasy Mini Kit (Qiagen),
according to the manufacturer’s protocol. mRNA was quantified with a
NanoDrop ND-1000 Spectrophotometer (Thermo Scientific, Waltham, Mass)
and converted to cDNA by using RevertAid Reverse Transcriptase and
complementary reagents (Fermentas, Thermo Scientific). Relative quantifi-
cation of IL1RL1 relative to the 18S housekeeping genewas conducted in trip-
licate by means of real-time quantitative PCR with the TaqMan primers
Hs01073300 and Hs00249389 (Applied Biosystems, Life Technologies,
Paisley, United Kingdom).
sST2 ELISA
Concentrations of sST2 protein in cell-culture supernatants were quantified
by using a Human ST2 ELISA DuoSet (R&D Systems), according to the
manufacturer’s protocol.
LUVA cell culture and IL-33 bioassay
The LUVA mast cell line was a kind gift from Dr J. Steinke, University of
Virginia.E1 LUVA cells were expanded in flasks in StemPro-34 serum free me-
diumwith associated nutrient supplement (Gibco, Life Technologies), L-gluta-
mine (Gibco, Life Technologies), and 1% penicillin-streptomycin (10,000 U/
mL, Gibco, Life Technologies). For the IL-33 bioassay, LUVA cells were
cultured for 24 hours at 0.5 million cells/mL in RPMI 1640 supplemented
with 10% FBS, 2 mmol/L L-glutamine, and gentamicin. The cell cultures
were stimulated with a concentration series of recombinant IL-33 or IFN-g
plus IL-4 in the presence/absence of recombinant sST2-Fc chimera, isotype-
Fc chimera, 100 nmol/L 1,25(OH)D3, or 40% HNEC conditioned medium.
Cell-surface expression of CD54 (intercellular adhesion molecule 1) was
measured by means of flow cytometry with a phycoerythrin-labeled anti-
human CD54 antibody (BioLegend, London, United Kingdom) and appro-
priate isotype control on a FACSCalibur flow cytometer (BD Biosciences,
San Jose, Calif) for initial experiments (Figs 2, B, and E2, B) and an Attune
flow cytometer (Life Technologies, Paisley, United Kingdom) for later exper-
iments (Fig 2, A and C-E, and Fig E2, C-E). Surface expression of CD54 was
quantified as the geometric mean fluorescence intensity (GeoMFI). For stim-
ulated LUVA cell cultures, induction of CD54 was calculated as the CD54
GeoMFI for unstimulated cell cultures subtracted from the GeoMFI for stim-
ulated cell cultures in that experiment. The percentage reduction in stimulus-
induced CD54 expression on LUVA cells cultured with vitamin D–treated
epithelial cell–conditioned medium compared with induction of CD54 with
control conditioned medium for each stimulus concentration was calculated
to analyze the effect of vitamin D–treated epithelial cell–conditioned medium
on stimulus-induced CD54 expression by LUVA cells.
Statistical analysis
Data were analyzed with GraphPad Prism 6 software (GraphPad Software,
La Jolla, Calif). For analysis of parametric data, t tests, repeated-measures
ANOVA, and 2-way repeated-measures ANOVA were used with posttest-
corrected multiple comparisons where the ANOVA was significant. For
nonparametric data, Wilcoxon matched-pairs signed-rank tests or Friedman
tests (with Dunn multiple comparison tests for comparison with control con-
ditions) were used. Unless otherwise stated, parametric data are shown as
means 6 SEMs, and nonparametric data are shown as box and whisker plots
with medians, 25th to 75th percentiles, and minimum to maximum ranges.
REFERENCE
E1. Laidlaw TM, Steinke JW, Tinana AM, Feng C, Xing W, Lam BK, et al. Charac-
terization of a novel human mast cell line that responds to stem cell factor and
expresses functional FcεRI. J Allergy Clin Immunol 2011;127:815-22.
J ALLERGY CLIN IMMUNOL
MARCH 2015
827.e1 LETTERS TO THE EDITOR
FIG E1. Further data on the effect of vitamin D on IL1RL1 expression. A and B, 1,25(OH)D3 (100 nmol/L) in-
creases the expression of mRNA for CAMP in primary human eosinophils (Fig E1, A) and LUVA mast cells
(Fig E1, B) but not mRNA for IL1RL1, as measured by using the Hs01073300 probe set in either cell type (n5
5 for both cell types). C and D, 25(OH)D3 (100 nmol/L) increases the expression of mRNA for both IL1RL1 and
CAMP in HBECs (Fig E1, C) but not in CD41 lymphocytes (Fig E1, D; Fig E1, C: n5 5; Fig E1, D: n5 3). *P <_ .05
and **P <_ .01.
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FIG E2. Stimulation with IL-33 induces LUVA cell expression of CD54. A and B, IL-33 causes homotypic ag-
gregation of LUVA cells (310 magnification; Fig E2, A) associated with increased expression of CD54 (filled
gray histogram, unstained; dashed line, isotype control; solid line, anti-CD54; Fig E2, B). C, Inhibition of IL-
33–induced LUVA cell CD54 expression by the recombinant sST2-Fc chimera is not observedwith an isotype
Fc chimera (n 5 3). D, IFN-g plus IL-4–induced LUVA cell CD54 expression is not inhibited by addition of re-
combinant sST2-Fc chimera (n 5 4). E, Effect of IL-33 on LUVA cell CD54 expression is not affected by addi-
tion of active vitamin D (100 nmol/L 1,25[OH]D3) directly to the LUVA cells (n 5 4).
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